Literature DB >> 30696359

Mesenchymal Stromal Cells Derived from Normal Cervix and Cervical Cancer Tumors Increase CD73 Expression in Cervical Cancer Cells Through TGF-β1 Production.

Luis Roberto Ávila-Ibarra1,2,3, María de Lourdes Mora-García2, Rosario García-Rocha2, Jorge Hernández-Montes2, Benny Weiss-Steider2, Juan José Montesinos4, Marcela Lizano Soberon5, Patricia García-López6, Christian Azucena Don López2, Daniela Berenice Torres-Pineda1,3, Rommel Chacón-Salinas7,8, Luis Vallejo-Castillo7,9, Sonia Mayra Pérez-Tapia7,8, Alberto Monroy-García1,2.   

Abstract

Mesenchymal stromal cells (MSCs) in the tumor microenvironment (TME) participate together with tumor cells to suppress antitumor effector cells through the production of immunosuppressive factors, such as transforming growth factor-beta 1 (TGF-β1). Furthermore, TGF-β1 can induce 5'-nucleotidase (CD73) expression in various cell types; this functional activity is associated with the production of adenosine (Ado), which is an immunosuppressive nucleoside. In this study, we provide evidence that coculture of MSCs derived from cervical tumors (CeCa-MSC) with CeCa tumor cells increases CD73 expression in tumor cells and the capacity of these cells to generate Ado in a MSC ratio-dependent manner. Interestingly, the increase in CD73 in the CeCa cell membrane corresponded to an increase in the TGF-β1 expression level in the tumor cells and the TGF-β1 content in the supernatants of the CeCa/CeCa-MSC cocultures. The addition of anti-hTGF-β neutralizing antibodies strongly reversed CD73 expression in the tumor cells. This phenomenon was not exclusive to CeCa-MSCs; coculture of MSCs derived from the normal cervix with CeCa cells produced similar results. These results suggest that the interaction of MSCs with CeCa tumor cells in the TME may condition higher TGF-β1 production to maintain an immunosuppressive status not only through the activity of this cytokine per se but also through its ability to induce CD73 expression in tumor cells and generate an immunosuppressive microenvironment rich in Ado.

Entities:  

Keywords:  CD73; TGF-β; adenosine; cervical cancer; mesenchymal stromal cells

Mesh:

Substances:

Year:  2019        PMID: 30696359     DOI: 10.1089/scd.2018.0183

Source DB:  PubMed          Journal:  Stem Cells Dev        ISSN: 1547-3287            Impact factor:   3.272


  5 in total

Review 1.  Tumor-resident adenosine-producing mesenchymal stem cells as a potential target for cancer treatment.

Authors:  Samaneh Arab; Akram Alizadeh; Samira Asgharzade
Journal:  Clin Exp Med       Date:  2021-01-23       Impact factor: 3.984

2.  Upregulation of CD73 Confers Acquired Radioresistance and is Required for Maintaining Irradiation-selected Pancreatic Cancer Cells in a Mesenchymal State.

Authors:  Anna M Nguyen; Jianhong Zhou; Brihget Sicairos; Sangeetha Sonney; Yuchun Du
Journal:  Mol Cell Proteomics       Date:  2019-12-26       Impact factor: 5.911

3.  Therapeutic efficacy and mechanism of CD73-TGFβ dual-blockade in a mouse model of triple-negative breast cancer.

Authors:  Yun Xing; Zhi-Qiang Ren; Rui Jin; Liang Liu; Jin-Peng Pei; Ker Yu
Journal:  Acta Pharmacol Sin       Date:  2022-01-26       Impact factor: 7.169

4.  Mesenchymal stem/stromal cells-derived IL-6 promotes nasopharyngeal carcinoma growth and resistance to cisplatin via upregulating CD73 expression.

Authors:  Jincheng Zeng; Shasha Chen; Caihong Li; Ziyu Ye; Bihua Lin; Yanfang Liang; Bin Wang; Yan Ma; Xingxing Chai; Xin Zhang; Keyuan Zhou; Qunzhou Zhang; Haitao Zhang
Journal:  J Cancer       Date:  2020-02-03       Impact factor: 4.207

5.  CCR7 Has Potential to Be a Prognosis Marker for Cervical Squamous Cell Carcinoma and an Index for Tumor Microenvironment Change.

Authors:  Wei-Jie Tian; Peng-Hui Feng; Jun Wang; Ting Yan; Qing-Feng Qin; Dong-Lin Li; Wen-Tong Liang
Journal:  Front Mol Biosci       Date:  2021-04-01
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.